Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
In this study, investigators are trying to see if LMP specific cytotoxic T lymphocytes (CTLs)
will prevent or treat disease called Epstein Barr Virus (EBV) Disorder including either
Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV
infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after
treatment, including the best treatment. Investigators are using special immune system cells
called third party LMP specific cytotoxic T lymphocytes (CTLs), a new experimental therapy.
Some patients with Lymphoma or SCAEBV or Leiomyosarcoma show evidence of infection with the
virus that causes infectious mononucleosis Epstein Barr virus (EBV) before or at the time of
their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's
and non-Hodgkin Lymphoma, suggesting that it may play a role in causing Lymphoma. The cancer
cells (in lymphoma) and some B cells (in SCAEBV) infected by EBV are able to hide from the
body's immune system and escape destruction. The investigators want to see if special white
blood cells, called T cells, that have been trained to kill EBV infected cells can survive in
patient's blood and affect the tumor or infection.
Investigators used this sort of therapy to treat a different type of cancer that occurs after
bone marrow or solid organ transplant called post transplant lymphoma. In this type of cancer
the tumor cells have 9 proteins made by EBV on their surface. They grew T cells in the
laboratory that recognized all 9 proteins and were able to successfully prevent and treat
post transplant lymphoma. However in Hodgkin Lymphoma, the tumor cells and B cells only
express 2 EBV proteins. In a previous study they made T cells that recognized all 9 proteins
and gave them to patients with Hodgkin Lymphoma. Some patients had a partial response to this
therapy but no patients had a complete response. They think one reason may be that many of
the T cells reacted with proteins that were not on the tumor cells. In this present study the
investigators are trying to find out if the investigators can improve this treatment by
growing T cells that recognize proteins expressed on EBV infected Lymphoma cells and B cells
called LMP-1 and LMP2. These special T cells are called third party LMP 1/2 -specific
cytotoxic T-lymphocytes (CTLs). These LMP-specific cytotoxic
T cells are an investigational product not approved by the Food and Drug Administration.